Advertisement

Predictive risk-score model to select patients with intrahepatic cholangiocarcinoma for adjuvant chemotherapy

Published:November 02, 2022DOI:https://doi.org/10.1016/j.hpb.2022.10.011

      Abstract

      Background

      The aim of this study was to develop a predictive model to identify individuals most likely to derive overall survival (OS) benefit from adjuvant chemotherapy (AC) after hepatic resection of intrahepatic cholangiocarcinoma (ICC).

      Methods

      Patients who underwent hepatic resection of ICC between 1990 and 2020 were identified from a multi-institutional database. Factors associated with worse OS were identified and incorporated into an online predictive model to identify patients most likely to benefit from AC.

      Results

      Among 726 patients, 189 (26.0%) individuals received AC. Factors associated with OS on multivariable analysis included CA19-9 (Hazard Ratio [HR]1.17, 95%CI 1.04–1.31), tumor burden score (HR1.09, 95%CI 1.04–1.15), T-category (T2/3/4, HR1.73, 95%CI 1.73–2.64), nodal disease (N1, HR3.80, 95%CI 2.02–7.15), tumor grade (HR1.88, 95%CI 1.00–3.55), and morphological subtype (HR2.19, 95%CI 1.08–4.46). A weighted predictive score was devised and made available online (https://yutaka-endo.shinyapps.io/ICCrisk_model_for_AC/). Receipt of AC was associated with a survival benefit among patients at high/medium-risk (high: no AC, 0% vs. AC, 20.6%; medium: no AC, 36.4% vs. 40.8%; both p < 0.05) but not low-risk (low: no AC, 65.1% vs. AC, 65.1%; p = 0.73) tumors.

      Conclusion

      An online predictive model based on tumor characteristics may help identify which patients may benefit the most from AC following resection of ICC.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to HPB
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Singal A.K.
        • Vauthey J.N.
        • Grady J.J.
        • Stroehlein J.R.
        Intra-hepatic cholangiocarcinoma--frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center.
        J Cancer Res Clin Oncol. 2011; 137: 1071-1078https://doi.org/10.1007/s00432-010-0971-z
        • Banales J.M.
        • Marin J.J.G.
        • Lamarca A.
        • Rodrigues P.M.
        • Khan S.A.
        • Roberts L.R.
        • et al.
        Cholangiocarcinoma 2020: the next horizon in mechanisms and management.
        Nat Rev Gastroenterol Hepatol. 2020; 17: 557-588https://doi.org/10.1038/s41575-020-0310-z
        • Yao K.J.
        • Jabbour S.
        • Parekh N.
        • Lin Y.
        • Moss R.A.
        Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National center for Health statistics database.
        BMC Gastroenterol. 2016; 16: 117https://doi.org/10.1186/s12876-016-0527-z
        • Shaib Y.
        • El-Serag H.B.
        The epidemiology of cholangiocarcinoma.
        Semin Liver Dis. 2004; 24: 115-125https://doi.org/10.1055/s-2004-828889
        • Spolverato G.
        • Vitale A.
        • Cucchetti A.
        • Popescu I.
        • Marques H.P.
        • Aldrighetti L.
        • et al.
        Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma?.
        Cancer. 2015; 121: 3998-4006https://doi.org/10.1002/cncr.29619
        • Endo I.
        • Gonen M.
        • Yopp A.C.
        • Dalal K.M.
        • Zhou Q.
        • Klimstra D.
        • et al.
        Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection.
        Ann Surg. 2008; 248: 84-96https://doi.org/10.1097/SLA.0b013e318176c4d3
        • Tsilimigras D.I.
        • Sahara K.
        • Wu L.
        • Moris D.
        • Bagante F.
        • Guglielmi A.
        • et al.
        Very early recurrence after liver resection for intrahepatic cholangiocarcinoma: considering alternative treatment approaches.
        JAMA Surg. 2020; 155: 823-831https://doi.org/10.1001/jamasurg.2020.1973
      1. Network NCCN. NCCN clinical practice guidelines in oncology. Hepatobiliary cancers, [cited 2022 July 1]. https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf.

        • Edeline J.
        • Hirano S.
        • Bertaut A.
        • Konishi M.
        • Benabdelghani M.
        • Uesaka K.
        • et al.
        Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies.
        Eur J Cancer. 2022; 164: 80-87https://doi.org/10.1016/j.ejca.2022.01.009
        • Ebata T.
        • Hirano S.
        • Konishi M.
        • Uesaka K.
        • Tsuchiya Y.
        • Ohtsuka M.
        • et al.
        Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer.
        Br J Surg. 2018; 105: 192-202https://doi.org/10.1002/bjs.10776
        • Primrose J.N.
        • Fox R.P.
        • Palmer D.H.
        • Malik H.Z.
        • Prasad R.
        • Mirza D.
        • et al.
        Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.
        Lancet Oncol. 2019; 20: 663-673https://doi.org/10.1016/S1470-2045(18)30915-X
        • Reames B.N.
        • Bagante F.
        • Ejaz A.
        • Spolverato G.
        • Ruzzenente A.
        • Weiss M.
        • et al.
        Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis.
        HPB. 2017; 19: 901-909https://doi.org/10.1016/j.hpb.2017.06.008
        • Miura J.T.
        • Johnston F.M.
        • Tsai S.
        • George B.
        • Thomas J.
        • Eastwood D.
        • et al.
        Chemotherapy for surgically resected intrahepatic cholangiocarcinoma.
        Ann Surg Oncol. 2015; 22: 3716-3723https://doi.org/10.1245/s10434-015-4501-8
        • Tsilimigras D.I.
        • Mehta R.
        • Aldrighetti L.
        • Poultsides G.A.
        • Maithel S.K.
        • Martel G.
        • et al.
        Development and validation of a laboratory risk score (LabScore) to predict outcomes after resection for intrahepatic cholangiocarcinoma.
        J Am Coll Surg. 2020; 230: 381-391 e2https://doi.org/10.1016/j.jamcollsurg.2019.12.025
        • Buttner S.
        • Galjart B.
        • Beumer B.R.
        • van Vugt J.L.A.
        • van Eijck C.H.J.
        • Polak W.G.
        • et al.
        Quality and performance of validated prognostic models for survival after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.
        HPB. 2021; 23: 25-36https://doi.org/10.1016/j.hpb.2020.07.007
        • Amin M.B.
        • Greene F.L.
        • Edge S.B.
        • Compton C.C.
        • Gershenwald J.E.
        • Brookland R.K.
        • et al.
        The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.
        CA A Cancer J Clin. 2017; 67: 93-99https://doi.org/10.3322/caac.21388
        • Sasaki K.
        • Morioka D.
        • Conci S.
        • Margonis G.A.
        • Sawada Y.
        • Ruzzenente A.
        • et al.
        The tumor burden score: a new "Metro-ticket" prognostic tool for colorectal liver metastases based on tumor size and number of tumors.
        Ann Surg. 2018; 267: 132-141https://doi.org/10.1097/SLA.0000000000002064
        • Strasberg S.M.
        Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system.
        J Hepatobiliary Pancreat Surg. 2005; 12: 351-355https://doi.org/10.1007/s00534-005-0999-7
        • Dindo D.
        • Demartines N.
        • Clavien P.A.
        Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.
        Ann Surg. 2004; 240: 205-213https://doi.org/10.1097/01.sla.0000133083.54934
        • Bagante F.
        • Spolverato G.
        • Merath K.
        • Weiss M.
        • Alexandrescu S.
        • Marques H.P.
        • et al.
        Intrahepatic cholangiocarcinoma tumor burden: a classification and regression tree model to define prognostic groups after resection.
        Surgery. 2019; 166: 983-990https://doi.org/10.1016/j.surg.2019.06.005
        • Tsilimigras D.I.
        • Mehta R.
        • Paredes A.Z.
        • Moris D.
        • Sahara K.
        • Bagante F.
        • et al.
        Overall tumor burden dictates outcomes for patients undergoing resection of multinodular hepatocellular carcinoma beyond the milan criteria.
        Ann Surg. 2020; 272: 574-581https://doi.org/10.1097/SLA.0000000000004346
        • Murakami Y.
        • Uemura K.
        • Sudo T.
        • Hayashidani Y.
        • Hashimoto Y.
        • Nakamura H.
        • et al.
        Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma.
        Ann Surg. 2009; 250: 950-956https://doi.org/10.1097/sla.0b013e3181b0fc8b
        • Glazer E.S.
        • Liu P.
        • Abdalla E.K.
        • Vauthey J.N.
        • Curley S.A.
        Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins.
        J Gastrointest Surg. 2012; 16: 1666-1671https://doi.org/10.1007/s11605-012-1935-1
        • Mizuno T.
        • Ebata T.
        • Yokoyama Y.
        • Igami T.
        • Sugawara G.
        • Yamaguchi J.
        • et al.
        Adjuvant gemcitabine monotherapy for resectable perihilar cholangiocarcinoma with lymph node involvement: a propensity score matching analysis.
        Surg Today. 2017; 47: 182-192https://doi.org/10.1007/s00595-016-1354-0
        • Yamanaka K.
        • Hatano E.
        • Kanai M.
        • Tanaka S.
        • Yamamoto K.
        • Narita M.
        • et al.
        A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer.
        Int J Clin Oncol. 2014; 19: 485-489https://doi.org/10.1007/s10147-013-0578-x
        • Rangarajan K.
        • Simmons G.
        • Manas D.
        • Malik H.
        • Hamady Z.Z.
        Systemic adjuvant chemotherapy for cholangiocarcinoma surgery: a systematic review and meta-analysis.
        Eur J Surg Oncol. 2020; 46: 684-693https://doi.org/10.1016/j.ejso.2019.11.499
        • Horgan A.M.
        • Amir E.
        • Walter T.
        • Knox J.J.
        Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis.
        J Clin Oncol. 2012; 30: 1934-1940https://doi.org/10.1200/JCO.2011.40.5381
        • Lee G.C.
        • Gamblin T.C.
        • Fong Z.V.
        • Ferrone C.R.
        • Goyal L.
        • Lillemoe K.D.
        • et al.
        Facility type is associated with margin status and overall survival of patients with resected intrahepatic cholangiocarcinoma.
        Ann Surg Oncol. 2019; 26: 4091-4099https://doi.org/10.1245/s10434-019-07657-5
        • Lee G.C.
        • Ferrone C.R.
        • Tanabe K.K.
        • Lillemoe K.D.
        • Blaszkowsky L.S.
        • Zhu A.X.
        • et al.
        Predictors of adjuvant treatment and survival in patients with intrahepatic cholangiocarcinoma who undergo resection.
        Am J Surg. 2019; 218: 959-966https://doi.org/10.1016/j.amjsurg.2019.02.036
        • Rahnemai-Azar A.A.
        • Weisbrod A.B.
        • Dillhoff M.
        • Schmidt C.
        • Pawlik T.M.
        Intrahepatic cholangiocarcinoma: current management and emerging therapies.
        Expet Rev Gastroenterol Hepatol. 2017; 11: 439-449https://doi.org/10.1080/17474124.2017.1309290
        • Lee J.
        • Kang S.H.
        • Noh O.K.
        • Chun M.
        • Oh Y.T.
        • Kim B.W.
        • et al.
        Adjuvant concurrent chemoradiation therapy in patients with microscopic residual tumor after curative resection for extrahepatic cholangiocarcinoma.
        Clin Transl Oncol. 2018; 20: 1011-1017https://doi.org/10.1007/s12094-017-1815-y
        • Ecker B.L.
        • Vining C.C.
        • Roses R.E.
        • Maggino L.
        • Lee M.K.
        • Drebin J.A.
        • et al.
        Identification of patients for adjuvant therapy after resection of carcinoma of the extrahepatic bile ducts: a propensity score-matched analysis.
        Ann Surg Oncol. 2017; 24: 3926-3933https://doi.org/10.1245/s10434-017-6095-9
        • Quan B.
        • Li M.
        • Lu S.
        • Li J.
        • Liu W.
        • Zhang F.
        • et al.
        Predicting disease-specific survival for patients with primary cholangiocarcinoma undergoing curative resection by using a decision tree model.
        Front Oncol. 2022; 12824541https://doi.org/10.3389/fonc.2022.824541
        • Lurje G.
        • Bednarsch J.
        • Czigany Z.
        • Lurje I.
        • Schlebusch I.K.
        • Boecker J.
        • et al.
        The prognostic role of lymphovascular invasion and lymph node metastasis in perihilar and intrahepatic cholangiocarcinoma.
        Eur J Surg Oncol. 2019; 45: 1468-1478https://doi.org/10.1016/j.ejso.2019.04.019
        • Yamamoto Y.
        • Sugiura T.
        • Todaka A.
        • Okamura Y.
        • Ito T.
        • Ashida R.
        • et al.
        Surgical indication for advanced intrahepatic cholangiocarcinoma according to the optimal preoperative carbohydrate antigen 19-9 cutoff value.
        World J Surg. 2018; 42: 3331-3340https://doi.org/10.1007/s00268-018-4605-y
        • Sahara K.
        • Tsilimigras D.I.
        • Mehta R.
        • Bagante F.
        • Guglielmi A.
        • Aldrighetti L.
        • et al.
        A novel online prognostic tool to predict long-term survival after liver resection for intrahepatic cholangiocarcinoma: the "metro-ticket" paradigm.
        J Surg Oncol. 2019; 120: 223-230https://doi.org/10.1002/jso.25480
        • Wang Y.
        • Li J.
        • Xia Y.
        • Gong R.
        • Wang K.
        • Yan Z.
        • et al.
        Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy.
        J Clin Oncol. 2013; 31: 1188-1195https://doi.org/10.1200/JCO.2012.41.5984
        • Rabin B.A.
        • Gaglio B.
        • Sanders T.
        • Nekhlyudov L.
        • Dearing J.W.
        • Bull S.
        • et al.
        Predicting cancer prognosis using interactive online tools: a systematic review and implications for cancer care providers.
        Cancer Epidemiol Biomarkers Prev. 2013; 22: 1645-1656https://doi.org/10.1158/1055-9965.EPI-13-0513
        • Zhu A.X.
        • Borger D.R.
        • Kim Y.
        • Cosgrove D.
        • Ejaz A.
        • Alexandrescu S.
        • et al.
        Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets.
        Ann Surg Oncol. 2014; 21: 3827-3834https://doi.org/10.1245/s10434-014-3828-x